GlassScriptPhysician profile
Anthony Bieck
NPI 1053847178
$2,443.30
in general payments reported to CMS, 2019-2025
25 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $829 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $352.01 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $337.12 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $308.84 | 2024-2025 | |
| Abbvie INC. | $301.80 | 2024-2025 | |
| Novo Nordisk INC | $217.57 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $134.60 | 2024-2025 | Tymlos |
| Amgen INC. | $97.92 | 2024-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $82.37 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.94 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $63.55 | 2024 | |
| Merck Sharp & Dohme LLC | $47.38 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $46.08 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $42.62 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $42.29 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $39.43 | 2024 | Xelstrym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.18 | 2024 | |
| Abbott Laboratories | $35.41 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $34.32 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $33.27 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $27.77 | 2025 | |
| Seqirus USA INC | $25.43 | 2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $16.60 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.53 | 2025 | Jardiance |
| Sanofi Pasteur INC. | $14.56 | 2025 | |
| Organon LLC | $12.71 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Bieck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.